AML is a hematologic cancer that is clinically heterogeneous, with a wide range of clinical outcomes. DNA methylation changes are a hallmark of AML but are not routinely used as a criterion for risk ...
Bionano Genomics, Inc. (Nasdaq: BNGO) today announced highlights from the fourth and final day of Symposium 2026. Day 4 featured updates from some of the most advanced and high-volume cytogenetics and ...
Erratum: Measurement of Completeness and Timeliness of Linked Electronic Health Record Pharmacy Data for Early Detection of Nonadherence to Breast Cancer Adjuvant Endocrine Therapy The article by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results